P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung CancerJulia Rotow, C. Blakely, Trever G. Bivona et al.|Journal of Thoracic Oncology|2019Cited by 8
P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated ResultsC. Blakely, David M. Jablons, Anatoly Urisman et al.|Journal of Thoracic Oncology|2021Cited by 7